Navigation Links
Cephalon Reports Another Strong Quarter
Date:10/28/2008

Record Sales of $490 Million, Up 14 Percent over Third Quarter 2007

Company Raises Full Year 2008 Sales and Earnings Guidance Introduces 2009 Adjusted Net Income Guidance, Up 27 Percent over 2008

FRAZER, Pa., Oct. 28 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today reported third quarter 2008 sales of $489.7 million, compared to sales of $428.7 million for the third quarter of 2007, and at the high end of the company's guidance of $480 - $490 million. Net income for the quarter was $112.0 million and basic income per common share was $1.64. Excluding amortization expense and certain other items, adjusted net income was $92.9 million and basic adjusted income per common share for the quarter was $1.36, compared to $1.08 for the same period in 2007, exceeding the company's guidance of $1.25 to $1.35.

Central nervous system (CNS) franchise sales were $273.7 million during the quarter, a 19 percent increase compared to the same period last year. The Pain franchise sales were $117.2 million compared to $121.8 million in the third quarter of 2007. AMRIX(R) (cyclobenzaprine hydrochloride extended- release capsules) sales increased 20 percent over the second quarter 2008. Oncology franchise sales were $52.4 million, an increase of 131 percent versus 2007. Sales of TREANDA(R) (bendamustine hydrochloride) for Injection were $24.6 million for the quarter, an increase of 71 percent over the second quarter of 2008.

"More and more patients are benefiting from the novel therapies that we offer. This has resulted in record sales, and adjusted earnings that exceeded the high end of our guidance. These solid results, and our confidence in our current product portfolio, enabled us to raise our guidance for the remainder of this year and issue adjusted net income guidance for 2009 that exceeds today's First Call consensus," said Frank Baldino, Jr., Ph.D., Chairman and CEO. "Despite troubled economic conditions around the world, our
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... (PRWEB) May 22, 2013 iLuv Creative ... of accessories for the mobile lifestyle, announces they are ... protect, and manage multiple iPad devices efficiently. Winner of ... the 2012 Good Design award, MultiCharger-X is revolutionizing the ... wherever it is deployed. , MultiCharger-X (iAD910) ...
(Date:5/22/2013)... 22, 2013 The Conference Forum ... Innovations to Advance Clinical Trials conference taking place on ... Boston, MA. , Disruptive thinkers from Novartis, Pfizer, ... share bold approaches to reduce expensive infrastructure, engage patients ... needs to be big, or novel, or it must ...
(Date:5/22/2013)... BUFFALO, N.Y. , May 22, 2013 /PRNewswire/ ... exclusive license for a patent pending novel genomic ... a molecular diagnostic test that could help in ... (NEPC) prostate cancer.  Neuroendocrine prostate ... adenocarcinoma (PCA) that can arise de novo, but ...
(Date:5/22/2013)... and NEW ORLEANS , May ... the field of regenerative medicine, presented new data generated ... Analysis Group (a leading health economics consultancy) demonstrating the ... ulcers (DFU) and venous leg ulcers (VLU) place upon ... of this research, which reveal annual costs of up ...
Breaking Biology Technology:iLuv Now Shipping the All New MultiCharger-X 2iLuv Now Shipping the All New MultiCharger-X 3Disruptive Innovation Hits Clinical Trials, Dedicated Event Launches 2Empire Genomics Licenses Novel DNA Biomarker for Use in Diagnosing and Creating a Companion Diagnostic Test for Neuroendocrine Prostate Cancer 2Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 2Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 3Organogenesis Presents Findings from Groundbreaking Research Highlighting the Healthcare Resource and Economic Burden of Venous Leg Ulcers and Diabetic Foot Ulcers 4
... Insect, Plant, Bacteria, and Yeast Cells , ... , New Brunswick Scientific Co. ... 1-800-631-5417 or 1-732-287-1200; bioinfo@nbsc.com, www.nbsc.com/bi5.htm ... bottles have,become the lab standard in most fermentation and cell,culture research labs, lack of ...
... , , ... , ... for culturing cells in a BioFlo ,110 benchtop fermentor/bioreactor system. ... and control modules to,enable growth of a wide variety of cultures, ...
... Joseph Fox 1 , Joanne B. Connolly 2 , Matthew E. ... 1 Shimadzu Scientifi c Inc., Columbia, US; 2 Shimadzu Biotech/Kratos, UK ... Introduction , ... the analysis of complex peptide mixtures. These include (i) concentration and separation of ...
Cached Biology Technology:An Easy-to-Use Research Fermentor/Bioreactor 2An Easy-to-Use Research Fermentor/Bioreactor 3CHO Cell Culture Application Using a BioFlo 110 Benchtop Bioreactor 2CHO Cell Culture Application Using a BioFlo 110 Benchtop Bioreactor 3CHO Cell Culture Application Using a BioFlo 110 Benchtop Bioreactor 4LC-MALDI and MALDI-MS/MS for the Analysis of Complex Peptide Mixtures 2LC-MALDI and MALDI-MS/MS for the Analysis of Complex Peptide Mixtures 3LC-MALDI and MALDI-MS/MS for the Analysis of Complex Peptide Mixtures 4
(Date:5/22/2013)... cell powered buses, including a team from Simon ... processes and bus membrane durability. , The team ... in the operating cycle of the bus on ... study, led by SFU graduate student Natalia MaCauley, ... Burnaby-based Ballard Power Systems and funded by Automotive ...
(Date:5/22/2013)... potential environmental and human health effects from disposal ... has led scientists to recommend stronger government policies ... (Li-ion) battery materials. That,s the conclusion of a ... Science & Technology . , Oladele A. Ogunseitan ... become mainstays for powering everything from smart phones ...
(Date:5/22/2013)... Declines in the biodiversity of pollinating insects and wild ... new study. , Researchers led by the University of ... found evidence of dramatic reductions in the diversity ... the 1950s and 1980s. , But the picture brightened ... national biodiversity losses among bees, hoverflies and wild plants. ...
Breaking Biology News(10 mins):Tests lead to doubling of fuel cell life 2Encouraging signs for bee biodiversity 2Encouraging signs for bee biodiversity 3
... One in eight women will be diagnosed with breast ... the better the chance of successful treatment and long-term ... testing by mammography remains cumbersome, costly, and in many ... stage. A team based in the Dept. of Biomedical ...
... similarity to humans, mice have long been used to learn ... shine a light on the genetic factors that cause disease ... options to protect the human population. But this process, ... more challenging by the 5% difference between the humans and ...
... shown that a dramatic sea-level rise occurred at the onset ... as the Blling warming, approximately 14,600 years ago. This event, ... rapid collapse of massive ice sheets 14,600 years ago and ... are published in the 29 March 2012 issue of the ...
Cached Biology News:Detecting breast cancer's fingerprint in a droplet of blood 2New lab mice cut search for genetic links to disease by more than a decade 2New lab mice cut search for genetic links to disease by more than a decade 3Ice sheet collapse and sea-level rise at the Boelling warming 14,600 years ago 2
... designed for RNA aptamer screening and binding ... powerful Paraflo microfluidic on-chip synthesis platform. These ... comprehensive DNA/RNA Aptamer Microarray Service. ... Aptamer Microarray contains greater than 1500 known ...
... Microarrays designed for RNA aptamer screening and ... and powerful Paraflo microfluidic on-chip synthesis platform. ... be synthesized on-chip and LC Sciences can ... microarrays are available as part of our ...
... ,Schistosomal glutathione-S-transferase (GST) is commonly used as ... E. coli (1). The GSTTag sequence has ... in some cases the solubility of its ... properly folded form, GSTTag fusion proteins can ...
... with Medium High quality ready-to-use cryopreserved neural ... medium for growth and lineage commitment. Just ... from E18 fetal rat brain in the ... of in vitro stem/progenitor cells, neurons, astrocytes ...
Biology Products: